FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308376715> ?p ?o ?g. }

• W4308376715 abstract "<h3>Background</h3> V-domain Immunoglobulin Suppressor of T cell Activation (VISTA), an immune checkpoint regulator, is highly expressed in myeloid cells in the tumor microenvironment (TME). It has been shown in vitro and in vivo that VISTA inhibits T cell activation and prevent T cell recruitment into tumors. In patients, high VISTA expression is associated with poor prognosis and is also a potential mediator of resistance to current checkpoint therapies. VISTA is a very attractive new target for cancer immunotherapy. <h3>Methods</h3> Kineta has developed a clinical candidate anti-VISTA monoclonal antibody, KVA12.1, which demonstrates in human VISTA KI mice strong anti-tumor activities as a single agent and in combination with other check-point inhibitors in multiple syngenic tumor models. KVA12.1 is an IgG1 antibody targeting a unique epitope on VISTA that has been engineered to extend its half-life and reduce its immunoreactivity. These modifications introduced in the IgG1 backbone of the antibody could prevent possible adverse events related to a Cytokine Release Syndrome (CRS) when injected into cancer patients. <h3>Results</h3> We show here that the engineered IgG1 of KVA12.1 increases binding of the antibody to neonatal Fc-Receptor compared to the wild type IgG1 and reduces the binding to different FcRg receptors in particular FcgRIIIa involved in a strong immunoreactivity. We have also shown in previous work that KVA12.1 binds with the same potency and specificity to human and Non-human primate (NHP) VISTA. We have therefore conducted Non-GLP and GLP toxicological studies and demonstrated that KVA12.1 is very well tolerated in NHP, even after multiple high dose injections over a one-month period. No mortality or overt clinical signs have been observed, as well as no treatment-related findings for clinical pathology endpoints and no change of CRS cytokine levels, in particular IL6 and TNFa. The absence of CRS markers has also been confirmed in whole blood obtained from multiple human healthy donors. Besides, we have confirmed in these same NHP studies the extended PK of our antibody. KVA12.1 will be tested in a clinical trial in cancer patients with advanced solid tumors that have failed previous therapies with current standard of care. To guide our inclusion criteria, VISTA expression has been evaluated by immunohistochemistry on a large panel of human cancer tissue samples. <h3>Conclusions</h3> The clinical trial will start by the end of 2022 and will evaluate the safety and tolerability of KVA12.1 injected alone or in combination with pembrolizumab, as well as the Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) as a primary objective. Pharmacokinetics, immunogenicity and tumor responses will also be evaluated in this trial." @default.
• W4308376715 created "2022-11-11" @default.
• W4308376715 creator A5033860333 @default.
• W4308376715 creator A5041382682 @default.
• W4308376715 creator A5044955159 @default.
• W4308376715 creator A5056439788 @default.
• W4308376715 creator A5064081217 @default.
• W4308376715 creator A5077600893 @default.
• W4308376715 creator A5078064180 @default.
• W4308376715 creator A5091665990 @default.
• W4308376715 date "2022-11-01" @default.
• W4308376715 modified "2023-09-30" @default.
• W4308376715 title "425 KVA12.1: an anti-VISTA monoclonal antibody with strong single agent anti-tumor activity and no evidence of cytokine mediated toxicity" @default.
• W4308376715 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0425" @default.
• W4308376715 hasPublicationYear "2022" @default.
• W4308376715 type Work @default.
• W4308376715 citedByCount "1" @default.
• W4308376715 countsByYear W43083767152023 @default.
• W4308376715 crossrefType "proceedings-article" @default.
• W4308376715 hasAuthorship W4308376715A5033860333 @default.
• W4308376715 hasAuthorship W4308376715A5041382682 @default.
• W4308376715 hasAuthorship W4308376715A5044955159 @default.
• W4308376715 hasAuthorship W4308376715A5056439788 @default.
• W4308376715 hasAuthorship W4308376715A5064081217 @default.
• W4308376715 hasAuthorship W4308376715A5077600893 @default.
• W4308376715 hasAuthorship W4308376715A5078064180 @default.
• W4308376715 hasAuthorship W4308376715A5091665990 @default.
• W4308376715 hasBestOaLocation W43083767151 @default.
• W4308376715 hasConcept C126322002 @default.
• W4308376715 hasConcept C159654299 @default.
• W4308376715 hasConcept C170493617 @default.
• W4308376715 hasConcept C195616568 @default.
• W4308376715 hasConcept C203014093 @default.
• W4308376715 hasConcept C2776090121 @default.
• W4308376715 hasConcept C2776107976 @default.
• W4308376715 hasConcept C2777701055 @default.
• W4308376715 hasConcept C2778690821 @default.
• W4308376715 hasConcept C2779193416 @default.
• W4308376715 hasConcept C2780674031 @default.
• W4308376715 hasConcept C2780851360 @default.
• W4308376715 hasConcept C502942594 @default.
• W4308376715 hasConcept C542903549 @default.
• W4308376715 hasConcept C71924100 @default.
• W4308376715 hasConcept C86803240 @default.
• W4308376715 hasConcept C8891405 @default.
• W4308376715 hasConceptScore W4308376715C126322002 @default.
• W4308376715 hasConceptScore W4308376715C159654299 @default.
• W4308376715 hasConceptScore W4308376715C170493617 @default.
• W4308376715 hasConceptScore W4308376715C195616568 @default.
• W4308376715 hasConceptScore W4308376715C203014093 @default.
• W4308376715 hasConceptScore W4308376715C2776090121 @default.
• W4308376715 hasConceptScore W4308376715C2776107976 @default.
• W4308376715 hasConceptScore W4308376715C2777701055 @default.
• W4308376715 hasConceptScore W4308376715C2778690821 @default.
• W4308376715 hasConceptScore W4308376715C2779193416 @default.
• W4308376715 hasConceptScore W4308376715C2780674031 @default.
• W4308376715 hasConceptScore W4308376715C2780851360 @default.
• W4308376715 hasConceptScore W4308376715C502942594 @default.
• W4308376715 hasConceptScore W4308376715C542903549 @default.
• W4308376715 hasConceptScore W4308376715C71924100 @default.
• W4308376715 hasConceptScore W4308376715C86803240 @default.
• W4308376715 hasConceptScore W4308376715C8891405 @default.
• W4308376715 hasLocation W43083767151 @default.
• W4308376715 hasOpenAccess W4308376715 @default.
• W4308376715 hasPrimaryLocation W43083767151 @default.
• W4308376715 hasRelatedWork W2984962695 @default.
• W4308376715 hasRelatedWork W3039388108 @default.
• W4308376715 hasRelatedWork W3134152892 @default.
• W4308376715 hasRelatedWork W3153709335 @default.
• W4308376715 hasRelatedWork W3177607563 @default.
• W4308376715 hasRelatedWork W3217412908 @default.
• W4308376715 hasRelatedWork W4213275083 @default.
• W4308376715 hasRelatedWork W4281389645 @default.
• W4308376715 hasRelatedWork W4285731353 @default.
• W4308376715 hasRelatedWork W4378715746 @default.
• W4308376715 isParatext "false" @default.
• W4308376715 isRetracted "false" @default.
• W4308376715 workType "article" @default.